EASD


Also found in: Acronyms.
References in periodicals archive ?
Grant, EASD Chairperson of the guidelines Task Force and professor of medicine at the University of Leeds, UK said: Recent trials have shown the cardiovascular safety and efficacy of SGLT2 inhibitors and GLP-1 receptor agonists for type 2 diabetes.
Through this partnership, the annual EASD GGSD postgraduate medical education program initiated in 2012 will now host doctors working in the diabetes field in Pakistan.
(1.) European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO).
The new guidance was co-published in Diabetologia, the journal of EASD, and Diabetes Care, the journal of the ADA, during the annual meeting of EASD in Berlin, Germany on October 5.
"We are proud to call for this paradigm shift as the most logical and appropriate next steps in care through this joint consensus report with EASD," William T.
A gloved lubricated finger was inserted into the vagina, touching the posterior wall with gentle pressure, while the endoprobe was in the anal canal; during the process, the EASD, external anal sphincter defect angle (EASDA) and PBT were evaluated at the mid-anal canal level [5,10] on a frozen ultrasound picture.
Their results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Portugal (11-15 September).
According to the ADA/ EASD algorithm, initiating combination insulin injectable therapy should be considered when the blood glucose is [greater than or equal to] 300 mg/dL or HbA1c is [greater than or equal to] 10% or if the patient has symptoms of hyperglycemia (ie, polyuria, polydipsia).
[4] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO), "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease," Journal of Hepatology, vol.
Panjwani Center for Molecular Medicine and Drug Research (PCMD), University of Karachi, presented a poster in the 52nd Annual Meeting of European Association for the Study of Diabetes (EASD) held in Munich, Germany.
At the European Association for the Study of Diabetes (EASD) annual meeting in September, researchers presented results of a placebo-controlled study of 7,020 patients, in which the T2D drug reduced the chances of death from cardiovascular disease by 38 percent, the risk of hospitalization by 35 percent and death from any cause by 32 percent.
At the recent 51st European Association for the Study of Diabetes (EASD) Annual Meeting in Stockholm, new Phase 3 data on Merck's investigational once-weekly oral DPP-4 inhibitor, omarigliptin, and additional findings from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) of Januvia were presented.